Nilotinib is a selective inhibitor of BCR-ABL approved for use in newly diagnosed and imatinib-resistant or -intolerant patients with chronic myeloid leukemia (CML) in chronic phase. In this study, 400 mg of nilotinib was administered twice daily to the patients with myeloid (MBP, n ¼ 105) or lymphoid blastic phase (LBP, n ¼ 31) CML. After a minimum follow-up of 24 months, major hematologic responses were observed in 60% (MBP) and 59% (LBP) of patients. Major cytogenetic responses (MCyR) were attained in 38% (MBP) and 52% (LBP) of patients; and complete cytogenetic responses in 30% and 32%, respectively. Median duration of MCyR was 10.8 (MBP) and 3.2 months (LBP). Median overall survival was 10.1 (MBP) and 7.9 (LBP) months with 12-and 24-month survival of 42% (MBP 44%, LBP 35%) and 27% (MBP 32%, LBP 10%), respectively. Twelve MBP patients and two LBP patients received subsequent stem cell transplantation. Myelosuppression was frequent, with grade 3/4 neutropenia, thrombocytopenia, and anemia in 68%, 63% and 47% of patients, respectively. Grade 3/4 hypophosphatemia, hyperbilirubinemia and lipase elevation were observed in 15%, 11% and 11% of patients, respectively. Nilotinib has significant efficacy in patients with BP CML, but given the limited long-term survival of these patients, novel agents are needed.
INTRODUCTION
Current therapies for patients with advanced phase chronic myeloid leukemia (CML) are inadequate, with median duration of overall survival (OS) from diagnosis of blastic phase (BP) disease of B6 --9 months; the great majority of patients alive 41 year from diagnosis with BP have received stem cell transplantation (SCT). 1, 2 Most of the patients with BP CML can be immunophenotypically defined as having myeloid blastic phase (MBP) or lymphoid blastic phase (LBP) disease. 1, 3 Imatinib mesylate (Glivec, Gleevec; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA), the prototypic BCR-ABL kinase inhibitor, has modest activity in patients with BP, with sustained complete hematologic responses (CHR) and complete cytogenetic responses (CCyR) in B7 --13% of patients and an estimated median duration of OS of B7 months. 2 Nilotinib hydrochloride monohydrate (Tasigna; Novartis Pharmaceutical Corporation, East Hanover, NJ, USA), a high-affinity aminopyrimidine-based ATP competitive inhibitor of BCR-ABL, has significant activity in patients with chronic phase (CP) CML who have failed or are intolerant of imatinib therapy. 4 Nilotinib has also recently been shown to be more effective than imatinib as frontline therapy for CP CML in terms of achievement of CCyRs, major cytogenetic responses (MCyRs), major molecular remissions and lower rates of disease progression to accelerated phase (AP) or BP. 5, 6 Because of nilotinib's activity in patients with CP or AP CML who have failed imatinib therapy and in patients with BP, noted in the nilotinib phase I study, 7 an international, open-label, multicenter, phase II study of nilotinib in patients with imatinib failure in BP was conducted.
MATERIALS AND METHODS
Adults with CML in BP who had imatinib resistance or intolerance received oral nilotinib at a starting dose of 400 mg twice daily on an empty stomach. Patients were allowed a dose increase of nilotinib to 600 mg twice daily if therapy was well tolerated and patient showed a suboptimal response. Definitions for BP CML, imatinib resistance or intolerance, and for disease progression were as previously reported. 7 Response assessments included CHR, marrow response (MaR; no blasts in peripheral blood, neutrophil count X1.0 Â 10 9 /l, platelet count X20 Â 10 9 /l and basophils o5%) and major hematologic response (MHR), which was defined as achievement of MaR or CHR where (i) MaR is precisely as defined here, and (ii) CHR is no blasts in peripheral blood, neutrophil count X1.5 Â 10 9 /l, platelet count X100 Â 10 9 /l and basophils o5%. McyR was defined as CCyR, (0% Philadelphia chromosome-positive (Ph þ ) metaphase cells) or partial cytogenetic response (PCyR, 40 to p35% Ph þ cells). Other study end points were duration of MHR and MCyR, and OS. Analyses of time to MHR and duration of MHR were restricted to patients who were not in MHR at the time of study entry. Baseline assessment of BCR-ABL mutation phenotype was performed where possible. 8 Adverse events were assessed continuously and were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. Efficacy analyses were performed for all the patients who received at least one dose of nilotinib. Twosided 95% exact confidence intervals were calculated for response rates. Duration of response was measured from the first day so that relevant criteria were met until either discontinuation due to disease progression or death; response duration was censored for patients who discontinued for reasons other than disease progression or death at the time of their last assessment. OS was estimated by Kaplan --Meier method. All patients had a minimum observation time of 24 months or discontinued early. The data cutoff was June 6, 2008.
RESULTS
One hundred and thirty-six patients were entered on study. Baseline patient demographics are summarized in Table 1 . The best previous response to imatinib was either stable or progressive disease in 46% of patients, with only 10% and 11% achieving previous CHR or MCyR, respectively. The other 33% of patients had best prior response of: return to CP (4%), MR (4%), minimal CyR (o1%), minor CyR (o1%) or unknown (22%).
Patients were intensively pretreated, with 37% having received prior cytarabine therapy and 13% having received a prior SCT. More than half of the patients had cytogenetic abnormalities in addition to the Philadelphia chromosome. Baseline distribution of BCR-ABL mutation genotypes is summarized in Table 2 . Mutation analysis was performed in 114 patients at baseline, 43 (38%) of whom had detectable mutations. T315I mutations were detected in 1% of patients in MBP and 7% of patients in LBP.
Of 119 patients who did not have a hematologic response at baseline, 71 (60%) achieved this milestone on nilotinib therapy---54 of 90 (60%) in MBP and 17 of 29 (59%) in LBP; a CHR was obtained in 24% and 21% patients, respectively. Median time to MHR was 1.4 months overall, 1.9 months for patients in MBP and 1.2 months for patients in LBP. The median duration of MHR was 24.7 months (range 10.6 --27.7) for patients in MBP and 12.9 months (range 4.5 --17.8) for patients in LBP. At 12 and 24 months, 63% and 51% of patients in MBP, and 57% and 21% of patients in LBP, respectively, maintained MHR (Figure 1) .
Sixteen of 136 (12%) patients had a baseline cytogenetic response. An MCyR was observed in 56 of 136 (41%) patients, 40 of 105 (38%) patients in MBP and 16 of 31 (52%) patients in LBP, with a CCyR obtained in 30% and 32% patients, respectively. Median time to MCyR among responders was 1.2 months overall, 1.8 and 1.0 months in responders in MBP and LBP, respectively. Median duration of MCyR was 10.8 months for patients in MBP, with an estimated 44% maintaining response at 24 months, and 3.2 months for patients in LBP, among whom none were known to have maintained cytogenetic response at 24 months ( Figure 2 ). The median OS was 10.1 months for patients in MBP and 7.9 months for patients in LBP, with 12-and 24-month survival rates of 42% (44% MBP, 36% LBP) and 27% (32% MBP, 10% LBP), respectively ( Figure 3 ). Following a response to nilotinib therapy, 12 (11%) patients in MBP and 2 (6%) patients in LBP received SCT. Baseline BCR-ABL kinase domain mutation data were available for 86 of 105 patients in MBP and 28 of 31 patients in LBP; the presence or absence of a detectable mutation did not affect OS (Figure 4) . The median duration of nilotinib therapy on study was 84 days (range 3 --969) at a median dose intensity of 800 mg/day (range 317 --1113). Dose interruptions occurred in 38% of patients, which were usually related to myelosuppression and were of a median total duration of 10 days (range 1 --109). Adverse events were generally mild and were controlled in most cases by transient treatment interruptions and/or dose reductions. The most common non-hematologic drug-related adverse events were rash, nausea, diarrhea and vomiting; these were grade 3/4 in 0.7, 1.5, 0.7 and 0.7% of patients (Table 3) . Cytopenias were noted in the majority of patients in both MBP and LBP, but most patients had some cytopenia before nilotinib therapy (Table 4) . Biochemical abnormalities were observed in some patients, with grade 3/4 hypophosphatemia, increased bilirubin and lipase elevation observed in 15%, 11% and 11% of patients, respectively; two (1.5%) patients were removed from study because of a biochemical observation.
DISCUSSION
Blastic transformation in patients with CML continues to be a difficult therapeutic challenge. 9, 10 Studies have shown marked broad-spectrum genetic changes in leukemia cells at the time of BP transformation. 11 It is likely that in BP, mechanisms other than the primary BCR-ABL oncogenic driver become key to the pathophysiology of the leukemia. 12 Grossman et al. 13 have recently reported on a deep-sequencing study in a cohort of 39 patients in BP; 77% of patients had mutations, most commonly in RUNX1, ASXL1 or WT1, and 33% had secondary mutations in BCR-ABL. Aside from patients who undergo successful SCT, long-term survival following diagnosis of BP is rare. 1, 14 Much effort in frontline therapy of patients with CP CML is being directed towards reducing the rate of development of BP over that previously observed in patients receiving imatinib therapy. This has proven successful with nilotinib therapy in the frontline setting. 6 In this study, nilotinib therapy was associated with hematologic and cytogenetic responses in the majority of patients. These were rapidly attained at a pace equivalent to that observed with nilotinib therapy of imatinib-resistant patients in CP or AP. 15 --17 The adverse event profile of nilotinib in the patients in BP appears equivalent to the profile seen with this agent in other CML settings. There were no extramedullary adverse events or biochemical abnormalities that appeared increased in severity or incidence in comparison with nilotinib therapy of imatinibresistant patients in CP or AP or in the third-line setting following failure of both prior imatinib and dasatinib. 15, 16 Responses occurred among the patients with a broad spectrum of BCR-ABL mutations, which is consistent with nilotinib data in other imatinib-resistant CML populations. 15, 16 Nilotinib has no significant clinical activity against the T315I mutation, which was observed in 1% and 7% of patients in MBP and LBP, respectively, in this study. However, some responses were observed in these patients, which suggest that the observed mutated clone was not the only driver of imatinib resistance or disease progression in these patients. This phenomenon has been observed in patients with BP treated with dasatinib, which also has no significant activity against the T315I genotype, and in other cohorts of imatinib-resistant patients with CML. 18, 19 Aside from its activity against imatinib-resistant mutated BCR-ABL genotypes, nilotinib's activity in patients with BP might be explained in part by differences in CML CD34 þ cell accumulation of intracellular kinase inhibitor levels. Unlike imatinib, nilotinib has been reported to be neither dependent on active import by hOCT1 nor to be effluxed through the ATP-binding cassette transporters MDR1 (ABCB1), MRP1 (ABCC1), or ABCG2 (BCRP). 20 --24 Dasatinib, a BCR-ABL, SRC-family kinase inhibitor, has also been documented to have activity in patients with BP. 18 In patients in MBP (n ¼ 109) or LBP (n ¼ 48), MHR was observed in 34% and 35% patients, respectively, with MCyR in 33% and 52% patients, respectively. 25 Median OS was 11.8 and 5.3 months, respectively. The overall apparent equivalence in response rates and OS in patients with BP between nilotinib and dasatinib, two agents that have significant differences in terms of their spectrum of kinase inhibition, 26 suggest that either non-kinase dependent mechanisms are important in BP or the non-BCR-ABL kinases involved are not inhibited by either agent.
The currently reported data show that nilotinib can induce durable hematologic and cytogenetic responses in some patients with BP. These responses may be of particular value in allowing patients to receive SCT. However, in the absence of SCT, most responses are not durable, and novel approaches are required for patients in BP.
2 Nilotinib-based combinations, for example, with stem-cell-modifying agents, such as smoothened inhibitors, 27 p53 stabilization with human homolog double minute 2 inhibitions, 28 aurora kinase inhibitors, 29 --31 or autophagy modifiers, 12,32 would seem worthy of urgent study in these patients.
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